Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1FJW6)

Drug Name

BT8009 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Nectin cell adhesion molecule 4 (NECTIN4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enfortumab	DMFS63G	Urothelial carcinoma	2C92.0	Approved	[3]
Enfortumab vedotin	DMW5V4U	Urothelial carcinoma	2C92.0	Approved	[4]
ASG-22ME	DM0Z3JS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nectin cell adhesion molecule 4 (NECTIN4)	TTPO9EG	NECT4_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04561362) Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Bicycle Therapeutics.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4	Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022 Mar;72(2):165-182.
5	2011 Pipeline of Seattle Genetics.